A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen
A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen
The purpose of this study is to show that tislelizumab will improve overall survival in participants with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or third-line treatment setting.
This is a randomized, open-label, multicenter Phase 3 study in adult participants with histologically confirmed, locally advanced or metastatic (Stage IIIB or IV), NSCLC (squamous or non-squamous) who have disease progression during or after a platinum-containing regimen.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Porto AlegreRS, 900350-903, Brazil
São José do Rio Preto, 15090-000, Brazil
São Paulo, 01246-000, Brazil
Wuhan, Hubei 430030, China
Shanghai, Shanghai Municipality 200025, China
Chengdu, Sichuan 610071, China
Tianjin, Tianjin Municipality 300121, China
Hangzhou, Zhejiang 310003, China
Kaunas, 45427, Lithuania
Hamilton Waikato, 3204, New Zealand
Olsztyn, 10-357, Poland
Szklarska Porba, 58-580, Poland
Arkhangelsk, Arkhangelskaya oblast 163045, Russia
Saransk, Mordoviya, Respublika 430005, Russia
Moscow, Moscow 117837, Russia
Ryazan, Ryazan Oblast 390026, Russia
SaintPetersburg, Sankt-Peterburg 197022, Russia
SaintPetersburg, Sankt-Peterburg 197183, Russia
SanktPetersburg, Sankt-Peterburg 197758, Russia
Volgograd, Volgograd Oblast 400138, Russia
SaintPetersburg, 197758, Russia
Edirne, 22030, Turkey (Türkiye)
Stanbul, 34098, Turkey (Türkiye)